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epileptic drugs (AEDs) and their impact on quality of life (QOL) in
patients with epilepsy. Methods: In this cross-sectional study,
patients with epilepsy (age 418 years) receiving AEDs for at least 1
year were enrolled. Demographic, clinical, and treatment parameters
were recorded. QOL was measured using the modiﬁed Quality of Life in
Epilepsy Inventory-10 (QOLIE-10) questionnaire for epilepsy. Results:
Of 200 patients, 53.5% were males and 60% were younger than 30
years. Seizures were predominantly partial (58%) and of idiopathic
origin (61%). Monotherapy to polytherapy ratio was 1:1, with 70% of the
patients on one new AED. Clobazam (37%) was used most frequently
followed by phenytoin (25.5%), levetiracetam (23%), oxcarbazepine
(21.5%), and carbamazepine (21%). Patients on polytherapy experi-
enced a signiﬁcantly more number of adverse drug reactions than didee front matter Copyright & 2015, International S
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ndence to: Chanda Kulkarni, Division of Clinical Pthose on monotherapy (P o 0.0001). The mean QOLIE-10 score was
74.58  20.60. There was no signiﬁcant difference in seizure frequency,
number of adverse drug reactions, and QOLIE-10 score among patients
receiving old and new AEDs. Multiple linear regression analysis
identiﬁed increased seizure frequency (standardized β 0.157;
P ¼ 0.003), more number of AEDs (standardized β 0.107; P ¼ 0.05) as
well as adverse drug reactions (standardized β 0.692; P ¼ 0.0001) as
signiﬁcant predictors of poor QOL. Conclusions: Appropriate tools for
early detection, selection of rational and safer AED treatment options,
and regular monitoring for adverse effects play a crucial role in
achieving seizure freedom and optimal QOL in patients with epilepsy.
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Epilepsy, the second most common neurological condition after
headache, is characterized by recurrent seizures of cerebral origin.
Fifty million people in the world and an estimated 6 to 10 million
people in India suffer from epilepsy [1–3]. It is of concern that the
diagnosis and management of epilepsy is often suboptimal in
developing countries and in the European region [4,5].
Epilepsy is both a medical diagnosis and a social label [6]
because people with epilepsy face many psychosocial challenges
(anxiety, social stigma, difﬁculty in driving, unemployment) that
can negatively impact quality of life (QOL). Such growing recog-
nition of the importance of the psychosocial effects of epilepsy
has led to the need to quantify QOL in affected individuals.
Hence, appropriate antiepileptic drug (AED) use, along with
monitoring of adverse effects, and assessment of QOL as an
outcome measure are important in the management of epilepsy
to achieve optimal seizure control.
The measurement of QOL using validated tools such as
Quality of Life in Epilepsy Inventory-31 [7], Quality of Life in
Epilepsy Inventory-10 (QOLIE-10) [8], and short-form 36 health
survey [9] are popular. The evaluation of QOL is a relatively new
measure to assess patient-related outcome of AED treatment forepilepsy. Demographic characteristics, high seizure frequency,
and long duration of the disorder have been shown to correlate
strongly with poor QOL [10]. Although several new AEDs have
been licensed over the last decade, there are limited numbers of
studies that have examined the impact of AED pharmacotherapy
(type of AED/monotherapy, polytherapy/adverse drug reactions
[ADRs]) on QOL [4].
The present study was designed to evaluate patterns of AED
use and to examine the impact of factors, namely, demographic,
clinical, and pharmacotherapy characteristics, affecting QOL.Methods
Study Design and Sampling
This was a cross-sectional study conducted over 15 months
(January 2011–March 2012) at the Neurology Outpatient Depart-
ment of St. John’s Medical College, Bangalore, India. Institutional
Ethical Review Board approval was obtained. To be powered at
90% with 5% alpha error, 92 patients were needed for the study to
detect a difference of 10 SD in QOL scores between patients on
AED monotherapy and polytherapy. A random sample of 200ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
conﬂicts of interest with regard to the content of this article.
harmacology, St. John’s Medical College, Bangalore, India.
Table 1 – Sociodemographic proﬁle of patients with
epilepsy.
Parameters Category N ¼ 200,
n (%)
Sex Male 107 (53.5)
Female 93 (46.5)
Age (y) Mean age  SD/
median
31.46 
12.834/26
Marital status Married 118 (59)
Unmarried 82 (41)
Residence Urban 115 (57.5)
Semiurban 62 (31)
Rural 23 (11.5)
Education Primary school and
below
40 (20)
High school to PUC 94 (47)
Degree and
professionals
66 (33)
Employment Employed 96 (48)
Unemployed 72 (36)
Student 32 (16)
Per-capita income
(INR)
10,000–50,000 69 (34.5)
450,000 5 (2.5)
INR, Indian rupee; PUC, pre-university college.
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deemed adequate to detect a clinically meaningful difference in
QOL scores (10–11 points) across other variables [11].Selection Criteria and Data Collection
Patients with epilepsy (PWE) aged 18 years or older receiving
AEDs for at least 1 year and consenting to participate were
included. The International League Against Epilepsy classiﬁcation
of seizures and epileptic syndromes was followed [12]. Patients
with signiﬁcant disability, major psychiatric disorders, severe
medical comorbidity confounding QOL assessment, and an AED
change in the last 1 month were excluded.
A structured case record form was used to collect data on
sociodemographic, clinical, and treatment parameters. Seizure
burden was scored according to the Engel system [13] for seizure
frequency and burden in a quasi-logarithmic scale ranging from 0
to 12. Scores less than 5 were considered as no seizures. A score
of 5 denotes one to three seizures per year, and a score of 6
indicates 4 to 11 seizures per year. Seizure frequency of one per
month was scored as 7 to 12. Persons were said to be seizure free
if there was absence of disabling seizures for more than 12
months. Treatment data included generic names, daily dose,Table 2 – Clinical characteristics of seizures among patie
Variables Monotherapy (n ¼ 100
Seizure frequency
1 and above per month 9
4–11 per year 4
1–3 per year 51
Absent 36
Percentage of patients who reported ADR 47
Generalized seizures 49
Partial seizures 51
AED, antiepileptic drug; ADR, adverse drug reaction.
* P o 0.05.duration, and adverse reaction proﬁle after the administration
of AEDs.
The QOLIE-10, an abbreviated questionnaire consisting seven
domains and 10 items derived from the QOLIE-31, was used to
assess QOL [8,14]. The overall score ranged from 0 to 100, with
higher scores representing better QOL. We used the English
version of the QOLIE-10, and the question on driving was
modiﬁed to suit the Indian scenario. Patients conversant in
English completed the questionnaire, and the remaining patients
in the multilingual patient population were explained the ques-
tions in their respective languages and responses were recorded.
Statistical Analysis
Data were analyzed using SPSS version 20. Descriptive data were
expressed as mean  SD, median, interquartile range, and
percentages. The QOLIE-10 scores were expressed as mean 
SD with 95% conﬁdence intervals. Categorical variables were
compared using the chi-square test. Continuous variables were
analyzed using the unpaired t test and analysis of variance
(parametric), the Mann-Whitney U test, the Kruskal-Wallis test
(nonparametric), and the Spearman correlation coefﬁcient. The
signiﬁcant variables in univariate analysis were entered into a
stepwise multiple linear regression model to identify the signiﬁ-
cant predictors of poor QOL. Statistical signiﬁcance was set at
P o 0.05.Results
Demographic and Clinical Characteristics
A total of 200 patients who were recruited into the study fulﬁlled
the eligibility criteria. The majority were males (53.5%) and 60% of
patients were between 18-30 years. Type of seizure was partial in
116 (58%), generalized in 84 (42%), and 122 (61%) patients had an
idiopathic or cryptogenic origin for seizures. The common attrib-
utable etiologies for seizures were central nervous system infec-
tions (neurocysticercosis), vascular, degenerative disorders, and
head injury. Median age at onset of epilepsy was 18 years and
duration was 7.5 years. Seizure frequency was one to three per
year (Engel score 5) in 47% of the patients, and 30% were seizure
free for more than 12 months (Tables 1 and 2).
AED Treatment Proﬁle
AED monotherapy was received by 100 patients, dual therapy by
69 patients, triple therapy by 24 patients, four AEDs by 4 patients,
and ﬁve AEDs by 3 patients. There were 21 types of two-drug
combinations and 17 types of three-drug combinations. The
mean number of AEDs/person was 1.7  0.9, with 30% on old,nts on AED monotherapy and polytherapy.
) Polytherapy (n ¼ 100) Signiﬁcance level* (χ2 test)
14 P ¼ 0.003
19
43
24
75 P ¼ 0.0001
35 P ¼ 0.062
65
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and 3).
The most frequent new AED monotherapy received was
clobazam in 37% and oxcarbazepine in 20% of the patients. The
use of clobazam was also maximum (63%) in the polytherapy
regimen. A signiﬁcantly higher number of patients with partial
seizures received carbamazepine than did those with generalized
seizures (28.4% vs. 10.7%; P ¼ 0.003), while the use of sodium
valproate and lamotrigine was signiﬁcantly higher in patients
with generalized epilepsy (P ¼ 0.004 and 0.048, respectively).
The frequency of seizures and ADRs was signiﬁcantly higher
among patients on polytherapy than among those on monother-
apy (P ¼ 0.0001 and 0.003 respectively) (Tables 4 and 5) and was
strongly associated with a lower QOL score (P o 0.0001). The
median number of ADRs was 2.6% and involved the central
nervous system followed by the gastrointestinal system and skin.
There were 12 serious ADRs—hypersensitivity, drug-induced
hematological abnormalities, psychotic disturbances and com-
plex memory loss—and warranted drug discontinuation.
QOL in PWE
The overall QOLIE-10 score was 17.4 to 100, with a mean of 74.9 
20.6. Most had an optimal (450) or high QOLIE score (470), which
implied better QOL, while it was less than 50 in 14% of the
patients.
Relationship between QOLIE-10 Scores and Clinical
Characteristics
There was no signiﬁcant association between the demographic
variables and overall QOLIE-10 scores. Table 4 shows the relation-
ship of clinical and pharmacotherapy variables with the overall
QOLIE score. The mean QOLIE 10 score was signiﬁcantly higher in
seizure-free patients than in those with seizures (P ¼ 0.002).
Analysis of variance showed a signiﬁcant association between
QOL score and duration of time patients were seizure free (not
seizure free vs. 42 years vs. o2 years; P ¼ 0.006). Post hoc tests
showed signiﬁcantly higher QOLIE-10 scores in patients who
were seizure free for more than 2 years than in those who were
not seizure free (P ¼ 0.009). Seizure frequency and Engel scoreTable 3 – Pattern and extent of AED use as monotherapy
generalized seizures.
AEDs No. of patients
(N ¼ 200), n (%)
Monotherapy
(N ¼ 100), n
Poly
(N ¼
Old AEDs
Phenytoin† 51 (25.5) 17
Carbamazepine† 42 (21) 15
Sodium valproate 28 (14) 12
Phenobarbitone† 26 (13) 6
New AEDs
Clobazam† 74 (37) 11
Leviteracetam† 46 (23) 12
Oxcarbamazepine 43 (21.5) 20
Topiramate† 17 (8.5) 4
Lamotrigine 6 (3) 3
Clonazepam† 5 (2.5) 0
Zonisamide 2 (1) 0
Gabapentin 1 (0.5) 0
AED, antiepileptic drug.
* Chi-square test for difference in utilization of AEDs among patients wi
† The proportion of patients on polytherapy was signiﬁcantly higher thawere signiﬁcantly associated with QOLIE-10 score (Po 0.0001). On
post hoc tests, patients with an Engel score of more than 6 had a
signiﬁcantly lower score than did those with an Engel score of 5
to 6 (P ¼ 0.019) and less than 5 (P ¼ 0.0001). Patients on
monotherapy had a signiﬁcantly higher QOLIE score than did
those on polytherapy (P ¼ 0.012), with no signiﬁcant difference
between patients on old and new AEDs. A trend toward lower
QOLIE-10 score was seen among patients on combination therapy
and was statistically insigniﬁcant.
A signiﬁcantly lower QOLIE score was associated with a
younger age of onset of seizures (P ¼ 0.012), decreased time since
last seizure (Po 0.0001), an increased number of AEDs (P ¼ 0.022),
and a higher number of ADRs (P o 0.0001).Signiﬁcant Predictors of Poor QOL
Multiple linear regression analysis of signiﬁcant variables in
univariate analysis of overall QOLIE-10 score showed adjusted
R2 as 0.496 for the proposed model of study. An increased number
of ADRs (standardized β 0.692; P ¼ 0.0001), use of two or more
AEDs (standardized β 0.107; P ¼ 0.050), and higher seizure
frequency (standardized β 0.157; P ¼.003) were signiﬁcant
predictors of poor QOL in PWE.Comparison of AED Treatment between Old, New, and
Combined Therapy
Table 5 shows the pattern of the use of old, new, and combina-
tion AED therapy. The percentage of patients under each type of
AED therapy did not differ signiﬁcantly with respect to seizure
type, their frequency, and freedom. A total of 79.3% of the
patients on combination AEDs reported at least one ADR com-
pared with 55.8% on new and 48.3% on old AEDs (P ¼ 0.008). No
difference was observed in the overall QOLIE-10 scores between
the three types of AED therapy. Patients on combination therapy
had lower medication effect domain scores than did those on old
AEDs (P ¼ 0.031)./polytherapy among patients with partial and
therapy
100), n
Partial seizures
(N ¼ 116), n (%)
Generalized
seizures (N ¼ 84),
n (%)
P*
34 34 (29.3) 17 (20.2) 0.188
27 33 (28.4) 9 (10.7) 0.003
16 9 (7.8) 19 (22.6) 0.004
20 16 (13.8) 10 (11.9) 0.832
63 47 (40.5) 27 (32.1) 0.239
34 28 (24.1) 18 (21.4) 0.735
23 26 (22.4) 17 (20.2) 0.731
13 11 (9.5) 6 (7.1) 0.62
3 1 (0.9) 5 (6) 0.048
5 4 (3.4) 1 (1.2) 0.401
2 1 (0.9) 1 (1.2) 1
1 1 (0.9) 0 (0) 1
th partial and generalized seizures (P o 0.05 considered signiﬁcant).
n those on monotherapy for these AEDs (χ2 test; P o 0.05).
Table 4 – Univariate analysis showing the relation-
ship between clinical and pharmacotherapy vari-
ables and total QOLIE-10 score.
Variables QOLIE-10 score,
mean  SD
P*
Seizure type
Partial (n ¼ 116) 73.96  20.63 t ¼ 0.496
Generalized (n ¼ 84) 75.43  20.66 P ¼ 0.621
Seizure freedom
Yes (n ¼ 60) 81.43  17.63 t ¼ 3.187
No (n ¼ 140) 71.57  21.14 P ¼ 0.002
Seizure freedom†
No (n ¼140)‡ 71.57  21.14 F ¼ 5.262
o2 y (n ¼ 24) 79.4  17.67 P ¼ 0.006
42 y (n ¼ 36)‡ 82.74  17.73
Engel score†
o5 (n ¼ 60)§ 80.90  18.28 F ¼ 8.365
5–6 (n ¼ 117)§ 73.72  20.42 P o 0.0001
46 (n ¼ 23)§ 60.69  21.32
Family history
Yes (n ¼ 32) 74.28  19.81 t ¼ 0.090
No (n ¼168) 74.63  20.81 P ¼ 0.928
Comorbidities
Yes (n ¼ 52) 71.01  21.40 t ¼ 1.457
No (n ¼ 148) 75.83  20.24 P ¼ 0.147
Time delay in treatment
Yes (n ¼ 24) 72.64  23.03 t ¼ 0.49
No (n ¼ 176) 74.84  20.31 P ¼ 0.624
Therapy
Monotherapy (n ¼ 100) 78.22  18.03 t ¼ 2.53
Polytherapy (n ¼ 100) 70.93  22.39 P ¼ 0.012
Type of AED
Old (n ¼ 60) 78.12  17.15 F ¼ 2.561
New (n ¼ 77) 75.42  20.75 P ¼ 0.080
Combined (n ¼ 63) 69.97  22.82
Adverse drug reactions
Yes (n ¼ 122) 65.95  20.28 T ¼ 8.669
No (n ¼ 78) 88.06  12.21 P o 0.0001
Suicidality
Yes (n ¼ 9) 37.35  11.96 t ¼ 6.015
No (n ¼ 191) 76.33  19.23 P o 0.0001
AED, antiepileptic drug; ANOVA, analysis of variance; QOLIE-10,
Quality of Life in Epilepsy Inventory-10.
* Statistical signiﬁcance based on t test and ANOVA (P o 0.05
considered signiﬁcant for difference in mean scores).
† For seizure freedom and Engel score, Bonferroni post hoc test
was used to identify which of the two groups signiﬁcantly differ
among the three; results not shown, presented as text.
‡ Patients with seizure freedom for more than 2 years had a
signiﬁcantly higher score than did patients with no seizure
freedom (P ¼ 0.009).
§ Patients with an Engel score of more than 6 had a signiﬁcantly
lower score than did patients with both Engel score of 5 to 6
(P ¼ 0.019) and less than 5 (P o 0.0001).
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The ultimate goal of epilepsy treatment is no seizures and no
adverse effects with an optimal QOL. Adopting evaluation of QOL
outcomes in the standard management plan along with tradi-
tional measures of assessment of seizure frequency and adverse
effects is hence increasingly encouraged [15]. To address this
objective, the present study examined patterns of AED use andidentiﬁed the demographic, clinical, and pharmacotherapy char-
acteristics and their inﬂuence on QOL in PWE.
Demographic and Clinical Proﬁle
The study sample was characterized by younger age patients
unlike developed nations where increasing incidence is reported
in the older age groups [16]. Although the number of men was
higher, this was not statistically signiﬁcant in contrast to that
reported elsewhere [17]. There was a low rate of unemployment
in the productive age group (excluding housewives) in our study,
which is in contrast to a European study that recorded a higher
unemployment rate, which was attributed to the increased
frequency of seizures [10]. Many factors may account for this
difference, the most important being a greater compulsion
among males to earn as they are often the primary source of
support to the families.
The type of seizures was predominantly partial as against
most Indian studies carried out elsewhere that report the occur-
rence of primary generalized seizures [4]. In addition, the
observed lower incidence of absence seizures in our study as
compared to that in developed countries may probably be due to
its underdetection [16]. The occurrence of secondary epilepsy
among patients with partial seizures may be attributed to the
widespread availability of diagnostic technique such as com-
puted tomography/magnetic resonance imaging to identify single
ring-enhancing lesions, which is a characteristic of neurocysti-
cercosis and also points to the higher prevalence of taeniasis in
developing countries [18].
AED Treatment Proﬁle
The extent of monotherapy versus polytherapy was similar,
unlike most other studies in which monotherapy was the
preferred regime. Practice of polytherapy is not in line with the
recommended principles of epilepsy treatment. It is generally
agreed that if seizures persist after titration to the highest
tolerated dose of a single AED, the patient is given a trial of two
monotherapies followed by combination therapy [19]. Use of
polytherapy, however, may be explained by the fact that this
study was carried out in a tertiary care center in which patients
are often referred for difﬁcult to control seizures. In addition,
there is evidence that supports early initiation of polytherapy in
severe epilepsies, particularly when the ﬁrst AED is partially
effective and the probability of seizure freedom with monother-
apy is low [15].
Conventional AEDs such as phenobarbitone and valproate are
in frequent use in many Indian studies. Their use, however, was
replaced by higher proportions of newer AEDs such as clobazam,
oxcarbazepine, and levetiracetam. The reduced use of older AEDs
despite their low cost and once daily dosing, particularly pheno-
barbitone, may be explained by their high interaction potential
and cognitive adverse effect.
The utilization of new AEDs alone and as combination was
found to be higher (70%), a trend similar to that seen in European
countries [20], but that was for nonepileptic conditions and this
was not considered in the present study. A wide variation has
been reported to exist in the use of newer AEDs in different
regions and hospital settings in India, ranging from 3% in Eastern
India to 40% to 50% in central/southern India [21,22]. The ﬁndings
of our previous study had shown the use of newer AEDs as add
on with conventional AED treatment for which they were initially
licensed as against their use as monotherapy, seen in 25% of the
patients in the present study, indicating a change in prescribing
trends [21]. This is in accordance with the updated National
Institute for Health and Care Excellence guidelines, which rec-
ommend the use of newer AEDs as potential ﬁrst-line drugs for
Table 5 – Comparison of variables among groups of patients with epilepsy receiving old, new, and combined
AED therapy.
Variables Old AED (n ¼ 60) New AED (n ¼ 77) Combination AEDs
(n ¼ 63)
P
Seizure freedom (n ¼ 60), n (%) 22 (36.7) 23 (29.9.5) 15 (23.8) 0.132*
Engel score 4 6 (n ¼ 21), n (%) 4 (6.7) 7(9.1) 10 (15.9) 0.326*
ADRs Yes (n ¼ 122), n (%) 29 (48.3) 43 (55.8) 50 (79.3) 0.008*
Medication effects score, mean  SD 2.48  0.79† 2.36  0.86 2.08  0.94† 0.03‡
Cognitive functioning score, mean  SD 21.13  8.03 20.04  8.56 18.24  9.36 0.175‡
QOLIE-10 overall score, mean  SD 78.12  17.15 75.42  20.75 69.97  22.82 0.080‡
AED, antiepileptic drug; ANOVA, analysis of variance; QOLIE-10, Quality of Life in Epilepsy Inventory-10.
* Chi-square test (P o 0.05 considered signiﬁcant).
† Medication effect score signiﬁcantly lower with combination therapy than with old AEDs (post hoc Bonferroni test; P ¼ 0.031).
‡ Statistical signiﬁcance based on ANOVA.
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evidence-based practices.
The increasing use of clobazam as an adjunctive in dual and
triple regimens for both partial and generalized seizures observed
in our study may be justiﬁed on the basis of the fact that it is a
nonsedating benzodiazepine effective in various seizure types
and is well tolerated by all age groups. Although, in principle,
monotherapy is preferred, literature supports the efﬁcacy of
combination AEDs with different or multiple mechanisms of
action for improved seizure control, for example, sodium channel
blockers with GABAergic drugs—phenobarbitone and clobazam—
or with valproate [23]. The use of such combinations is well
accepted as rational prescribing. A few patients, however,
received two sodium channel blockers, which may increase the
possibility of inducing voltage-dependent sodium block with an
increased potential to produce neurotoxic adverse effects such as
ataxia, dizziness, and diplopia and may need careful attention.
The assumption that such an ADR will be induced is because a
relatively larger number of patients on polytherapy experienced
an ADR. Hence, careful evaluation of rational combinations of
AED polytherapy through regular clinical as well as drug-level
monitoring, if feasible, to prevent adverse drug-drug interactions
may be considered.
The pattern of AED treatment of partial seizures was found to
be similar to earlier studies and was as per recommended
guidelines [21,24,25], with a higher proportion of patients on
levetiracetam. A recently completed double-blind trial by Brodie
et al. [26] has shown that levetiracetam meets International
League Against Epilepsy class I criteria for noninferiority to
carbamazepine in newly diagnosed epilepsy in terms of efﬁcacy
and effectiveness. Subsequently, guidelines have been updated
(National Institute for Health and Care Excellence) to include
levetiracetam as a potential ﬁrst-line agent in partial seizures and
adjunctive in generalized seizures [15,19].
QOL in PWE
QOLIE-10, an abbreviated questionnaire used to study the impact
of different variables, in particular, pharmacotherapy character-
istics, showed an optimal QOL, with a mean score of 74.58 
20.60, which was higher than that reported in a study from
Kerala, India [4]. The previous studies have identiﬁed female
gender, marital status, low education level, and rural residence to
be signiﬁcantly associated with a low QOLIE score [17,27]. In
contrast, results of our study did not reveal any association
between demographic variables and QOLIE scores. On a positive
note, this may probably be because of the decreased stigma, good
social support, and increased awareness about epilepsy among
patients attending this tertiary care setup.In the present study, although lower age of onset of seizures
was found to be associated with a poor QOL, a ﬁnding reported by
Sinha et al. [17], the seizure type did not show an association,
unlike that reported in two Indian studies [4,28,29]. The clinical
signiﬁcance of this ﬁnding is difﬁcult to explain. The increase in
seizure frequency as one of the clinical characteristics has been
described as the most relevant determinant of poor QOL scores
consistently across many studies [17,28], a similar correlation
seen in the present study among patients receiving polytherapy.
Alternatively, longer seizure-free duration since the last episode
is positively correlated with a good QOL.
Patients on AED monotherapy had signiﬁcantly better QOL,
similar to that reported by Thomas et al. [4]; however, there was
no difference in the overall QOLIE-10 scores between old and new
AEDs. A study by Gilliam [30] demonstrated a similar ﬁnding in
seizure-free patients. Furthermore, AEDs’ adverse effects, with
depression as the only parameter in 195 patients with active
epilepsy, signiﬁcantly correlated with poor QOL (Po 0.0001). Also,
adverse effects from AED use were found to be the most
important factor associated with a worse QOL, even among 101
seizure-free patients who were treated with AEDs for epilepsy
[31]. The multivariate analysis including signiﬁcant variables in a
stepwise linear regression model in our study identiﬁed the
increasing number of ADRs to be the most important predictor
of poor QOL followed by seizure frequency and number of AEDs.
The analysis of the use of three types of AED therapies—old,
new, and combined—showed no difference in seizure frequency.
Also, a signiﬁcantly greater proportion of patients on combina-
tion therapy reported ADRs compared with those on old or new
AED monotherapy. The score in the medication effect domain
(question in this domain based on adverse effects of AED) among
those on combination therapy, however, was signiﬁcantly lower
than among those on old AEDs. This could have possibly elicited
a positive response from them when we queried them speciﬁcally
about individual ADRs and led to the lower score in the medi-
cation effects domain. Also, the possibility that these patients did
not tolerate the old AEDs well because of drug interactions/
enzyme induction and hence were administered new AEDs
cannot be ruled out.
It is generally assumed that newer AEDs have the same
efﬁcacy as older ones but have better tolerability. We observed,
however, the absence of a signiﬁcant difference in adverse effects
of AED or QOL scores between old and new AED monotherapy,
similar to the results of a study in seizure-free patients in the
Standard and New Antiepileptic Drugs trial. This trial provided
high external validity on the effectiveness of old and new AEDs in
a pragmatic setting. The trial reported lamotrigine to be most
effective when compared with carbamazepine and other new
AEDs in focal seizures and valproate to be more effective than
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 1 – 66topiramate and lamotrigine in generalized and unclassiﬁed epi-
lepsies. It is also now known that new AEDs are not completely
free of severe adverse effects, particularly the cognitive and
psychiatric adverse effects associated with topiramate and leve-
tiracetam, but have similar efﬁcacy as older AEDs in newly
diagnosed patients [32].
To our knowledge, this is the ﬁrst study in India that
evaluated the impact of speciﬁc pharmacotherapy characteristics
on QOL in PWE as well as the tolerability proﬁle of AED therapy in
a naturalistic setting. The pattern of AED use did not show a
signiﬁcant difference in use between older and newer AEDs.
A few limitations of the present study include the cross-
sectional design, which made it difﬁcult to comment with
certainty on the differences in efﬁcacy, tolerability, and QOLIE
scores between different AED therapies. Ideally, a follow-up study
with initiation of AED therapy within the same time frame
should enable measurement of difference in QOLIE scores from
baseline. Also, patients not conversant with English language had
to be explained the various domains in the questionnaire in a
local language to elicit responses. Findings, however, revealed
increase in seizure frequency, use of polytherapy, and number of
ADRs as poor predictors of QOL.
The ﬁndings are debatable because there was frequent use of new
AEDs, which are generally more expensive, raising the primary concern
whether their use should be promoted in developing countries where
medication costs are out-of-pocket expenses for patients. In addition,
the negative impact of AED polytherapy on QOL and the increased
number of adverse reactions emphasize the need to optimize mono-
therapy regimes. The key to epilepsy management is to adapt treat-
ment decisions to individual patient characteristics where the AED
choice is determined by patient-speciﬁc features such as age as
identiﬁed in the present study. The increase in the number of ADRs
with a low score in the medication effect domain among patients who
received combination therapy hints at the possibility of decreased
tolerability to old AEDs. Thus, where enzyme induction and drug
interactions are anticipated as signiﬁcant problems, resulting in reduced
tolerability with old AEDs especially in patients with comorbidities, new
drugs would be preferable because they play an important role in
difﬁcult to control epilepsy encountered in most tertiary care centers.Conclusions
We conclude that appropriate tools for early detection and
selection of safer AED treatment options, with careful monitor-
ing, recognition, and assessment of adverse effects of AEDs, play
a crucial role to move us closer to the ultimate goal of freedom
from seizures and to achieve optimal QOL in PWE.
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